Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Athenex logo — company profile

Athenex

Founded 2003 United States Buffalo, United States 89 employees Post-IPO Equity Total: $342.15M Biotechnology, Pharmaceutical

General Information

Company Name Athenex
Founded Year 2003
Location United States Buffalo, United States
Employees 89
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Athenex. To contact Athenex, visit athenex.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Athenex compare?

A PDF of Athenex and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Athenex soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Athenex

Athenex is a global specialty oncology pharmaceutical company founded in 2003 and headquartered in the United States. The company is dedicated to the development and commercialization of next generation therapies for cancer diseases and supportive therapies. With a focus on delivering innovative drugs that can have a life-changing impact on cancer patients, Athenex operates medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through its connected innovation and manufacturing supply chain presence, Athenex can identify, develop, and deliver proprietary medical technology across continents and multiple regulatory environments. The company's last investment of $30.00MPost-IPO Equity was made on 11 August 2022, marking a significant milestone in its growth. Although the specific investors for this round are not disclosed, it underscores confidence in Athenex's potential within the biotechnology and pharmaceutical industries.

Business keywords: oncology pharmaceutical, cancer therapies, innovation, manufacturing supply chain, global, specialty pharmaceuticals, drug development, life-changing impact, China, North America, proprietary medical technology, regulatory environments, connected innovation, global presence

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $30.00M -
11 Aug 2022
Post IPO Equity $60.00M 1
Kingdon Capital Management
Kingdon Capital Management
05 Dec 2019
Post IPO Equity $100.00M 2
OrbiMed Perceptive Advisors
OrbiMed, Perceptive Advisors
06 May 2019
Post IPO Equity $50.00M 1
Perceptive Advisors
Perceptive Advisors
02 Jul 2018
Private Equity Round $48.10M 1
Mandra Capital
Mandra Capital
20 May 2015
Private Equity Round $40.00M 1
Mandra Capital
Mandra Capital
05 Mar 2014
Venture Round $300.00K 1
Mandra Capital
Mandra Capital
23 Dec 2013
Venture Round $5.00M -
06 Aug 2012
Venture Round $4.67M -
25 Apr 2011
Venture Round $4.08M -
03 Feb 2010

Athenex Alternatives & Competitors

View All Alternatives
Athenex vs
EOC Pharma Group
EOC Pharma Group

Empowering cancer care in China through a robust network of global partnerships, innovative drug dev...

Series C
Biopharma, Biotechnology
Compare Athenex vs EOC Pharma Group
Athenex vs
AUROBINDO PHARMA LTD
AUROBINDO PHARMA LTD India

Committed to healthier life!

14923 employees
Biotechnology, Pharmaceutical
Compare Athenex vs AUROBINDO PHARMA LTD
Athenex vs
Anticancer Bioscience
Anticancer Bioscience China

Applying our synthetic lethality expertise for better cancer therapies

Seed
17 employees
Biotechnology, Health Care
Compare Athenex vs Anticancer Bioscience
View all alternatives

FAQ About Athenex

Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients...
Athenex was founded in 2003.
Athenex is headquartered in Buffalo, United States.
Athenex operates in Biotechnology and Pharmaceutical. Its work centres on oncology pharmaceutical, cancer therapies, innovation and manufacturing supply chain.
Athenex has approximately 89 employees.
Athenex has completed 10 funding rounds, raising a total of $342.15M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Athenex include EOC Pharma Group, AUROBINDO PHARMA LTD, Anticancer Bioscience, Biohaven, Reistone Biopharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Athenex and EOC Pharma Group are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Athenex, https://bouncewatch.com/company/athenex, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout